Published 4 years ago
May 2018
SYNSIGHT has received the certified Genopole as an innovative company in drug discovery and can integrate the incubator.
39
2
SYNSIGHT
Company
at
France
Primary tabs
About your organization
SYNSIGHT’s platform encompasses Artificial Intelligence, Molecular Modeling and High-Content Screening to rationalize and accelerate drug discovery projects of its partners.
La capacité prédictive de l’intelligence artificielle alliée à la capacité descriptive et explicative de la modélisation moléculaire, enrichie de données expérimentales quantitatives et fonctionnelles (permettant d’éduquer le modèle) constitue la plateforme de SYNSIGHT et sa valeur différenciante.
News
/5
Published 4 years ago
June 2018
SYNSIGHT obtains the certificate of HEC Challenge+ dedicated to entrepreneurs of innovative companies. Cyril Bauvais and Guillaume Bollot present their elevator pitch after 9 months of formation at HEC Campus.
Published 4 years ago
September 2018
SYNSIGHT is honored to participate in AI for Health, in Paris on September 2018. During this exciting event, SYNSIGHT presented is activity and Cyril Bauvais (CEO) exchanged about its vision related to AI in drug discovery. Thank you, Damien Gromier for inviting us to this exciting event, and Pierre-Antoine Beaudouin, for the great debate!
Published 4 years ago
September 2018
SYNSIGHT is proud to announce the launch of a state-of-the-art structural/biophysics unit within the company. Our native AI-powered Computer-Aided Drug Discovery (CADD) expertise and this new experimental unit will enable us to lead integrated drug discovery programs, from virtual screening to experimental validation. This unit will be built and managed by just hired in September, Nicolas Babault, former team leader at the Icahn School of Medicine at Mount Sinai – New York City.
Published 4 years ago
November 2018
The Netherlands embassy hosts SYNSIGHT for the Erasme-Descartes conference in collaboration with the French embassy. SYNSIGHT presents how AI is incorporated in its proprietary drug discovery platform.
Partners search
See detailed informationsPlateforme intégrée de criblage High-Content et Intelligence artificielle pour la modulation de Portein-Protein Interaction
Type of partnership
Offer
Scope of the partnership
Technological
Network (0)
There are no organizations in the network.
Dataroom
You are not connected
